Effects of renal impairment on a new time-resolved fluoroimmunoassay for serum digoxin N CPA T E R SON and M J S T E WAR T From the Department of Clinical Biochemistry. Royal lnfirmary, Glasgow G4 OSF. UK Digoxin is the most widely prescribed cardiac glycoside used for the treatment of atrial fibrillation and congestive cardiac failure. It is commonly measured by some form of immunoassay using commercially available kits. some of which have been reported to show cross-reaction with unidentified substances in patients who have renal impairment but who are not taking digoxin. I Similar findings have been reported from studies in neonates. hypertensive pregnant women. and patients in hepatic failure. I The cross-reactants have been designated digoxin-like immunoreactive factors (DLlF) .
This report assesses the extent of DLlFinterference in serum samples from patients with renal impairment. using a recently introduced dissociation-enhanced lanthanide fluoroimmunoassay (Delfin. LKB-Wallac. Turku, Finland) for digoxin.
Malerials and melhods
The Dclfia digoxin assay is a solid phase fluoroimrnunoassay based on a competitive reaction between immohilised digoxin and sample digoxin. using europium (Eu)-Iahelled polyclonal anti-digoxin antibodies. On completion of the immunoreaction. the unbound labelled antibody is removed by washing. and an enhancement solution is added to dissociate the Eu 1 + cations from the bound labelled antibody into solution where they form highly fluorescent chclates, Fluorescence measurements and data reduction were carried out using the Arcus 123()time-resolved fluorometer (LKB-Wallac).
Each Delfia kit was used in accordance with the manufacturer's recommendations. For comparative purposes. serum digoxin was also estimated using the Abbott TDx fluorescence were obtained from the routine laboratory workload. Medical records were used to confirm that none of these patients was receiving digoxin or any form of steroid therapy. Figure I shows the apparent digoxin concentrations in patients with and without renal impairment. as determined by Delfia and FPIA. None of the patients with normal renal function showed digoxin concentrations above the assay limit of detection (0,26 nmoVL) with either method. Seventeen patients with renal impairment (9 men and X women) aged 18-66 years. had apparent digoxin concentrations in the range ()·27-0·60 nmol/L when measured by the Delfia method. By comparison. only two patients with renal impairment had detectable apparent digoxin concentrations when measured by FPIA. We found the Delfia assay to have an intra-assay coefficient of variation (CY) of 6·6'1.) at 0·56 nmol/L (n=20), whilst the manufacturers quote an intra-assay CY of 6·8% at ().1)6 nmol/L (1/=25) for FPIA.
Resulls

Discussion
The presence of DLIF in the serum of some patients with renal impairment has been demonstrated using a number of immunoassays, •
•••••
9' 9' 9' 9' 9' 9' 9' 9' 9' '99'9' 9' 9' 9' ... 0·60 nmol/L in a significant number (17 out of 40) of patients with renal impairment who were not receiving digoxin. This apparent digoxin concentration is not explained by metabolites or drugs such as quinidine or verapamil, which are known to increase serum digoxin concentrations, since none of the patients included was receiving either drug. The steroid status of the patients included was not investigated. The apparent digoxin concentrations did not correlate with the degree of renal impairment, or with the age or sex of the patient. The amount of DLiF interference in patients with renal impairment was much less with FPIA. confirming previous results;' The physiological relevance of DLiF presence in serum is still unknown.' Suspected digoxin toxicity may be confirmed by detecting an elevated serum digoxin concentration above the narrow therapeutic range. The Delfia method with its current antibody may over-estimate digoxin concentrations in serum from patients with renal impairment, who are receiving digoxin, thus limiting the clinical value of the result.
We would suggest that all currently available digoxin assays he evaluated for DLIF interferences.
